Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Comparison of World Health Organization and International Consensus Classification Guidelines for Myeloid Neoplasms Harboring TP53 -Mutations Using an Independent International Cohort

Blood (2023) 142 (Supplement 1): 3243.

https://doi.org/10.1182/blood-2023-187860

Published: 2023

Journal Articles

Survival and Prognosis Among 301 Patients with Newly-Diagnosed Acute Myeloid Leukemia Following Venetoclax Plus Hypomethylating Agent Therapy

Blood (2023) 142 (Supplement 1): 591.

https://doi.org/10.1182/blood-2023-178837

Published: 2023

Journal Articles

Phase 1/2 Multicenter, Open-Label Study of CTX-712 in Patients with Relapsed/Refractory Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes

Aref Al-Kali, Antoine Saliba, Cecilia Y. Arana Yi, James M. Foran, Yasushi Tanoue, Maki Yamamoto, Joachim Gullbo, Guillermo Garcia-Manero

Blood (2023) 142 (Supplement 1): 3249.

https://doi.org/10.1182/blood-2023-173496

Published: 2023

Journal Articles

A Phase 1 Study of CD38-Bispecific Antibody (XmAb18968) for Patients with CD38 Expressing Relapsed/Refractory Acute Myeloid Leukemia

Guru Subramanian Guru Murthy, Jessica T. Leonard, Talha Badar, Cecilia Y. Arana Yi, Adam S Duvall, Bijal D. Shah, Arielle Baim, Tyce Kearl, Alexandra M. Harrington, Aniko Szabo, Ehab L. Atallah

Blood (2023) 142 (Supplement 1): 1541.

https://doi.org/10.1182/blood-2023-187721

Published: 2023

Journal Articles

Single-Hit TP53 mut Is Associated with Poor Outcomes in Therapy-Related but Not De Novo Myelodysplastic Syndromes: Importance of Clinical History

Blood (2023) 142 (Supplement 1): 4608.

https://doi.org/10.1182/blood-2023-187905

Published: 2023

Journal Articles

A Phase 1 Study of CD38-Bispecific Antibody (XmAb18968) for Patients with Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia

Guru Subramanian Guru Murthy, Bijal D. Shah, Adam S Duvall, Jessica T. Leonard, Talha Badar, Cecilia Y. Arana Yi, Tyce Kearl, Arielle Baim, Alexandra M. Harrington, Aniko Szabo, Ehab L. Atallah

Blood (2023) 142 (Supplement 1): 4242.

https://doi.org/10.1182/blood-2023-187468

Published: 2023

Journal Articles

A Phase 1 Study of Avapritinib in Combination with Decitabine in Patients with Systemic Mastocytosis with an Associated Hematologic Neoplasm

Andrew T. Kuykendall, Somedeb Ball, Jason Gotlib, Cecilia Y. Arana Yi, Tsewang Tashi, Raajit K. Rampal, Daniel J. DeAngelo, Virginia O. Volpe, Kristen Marie Pettit, Rami S. Komrokji, Eric Padron

Blood (2023) 142 (Supplement 1): 6441.

https://doi.org/10.1182/blood-2023-184652

Published: 2023

Journal Articles

Venetoclax + Cladribine + Low-Dose Cytarabine in Acute Myeloid Leukemia Relapsed or Refractory to Venetoclax + Hypomethylating Agent

Nickolas Steinauer, Kristen McCullough, Aref Al-Kali, Hassan Alkhateeb, Kebede Begna, Abhishek A Mangaonkar, Antoine Saliba, Mehrdad Hefazi, Mark R. Litzow, William J. Hogan, Mithun V Shah, Animesh D. Pardanani, Talha Badar, Hemant S. Murthy, James M. Foran, Cecilia Y. Arana Yi, Ayalew Tefferi, Naseema Gangat

Blood (2023) 142 (Supplement 1): 2853.

https://doi.org/10.1182/blood-2023-185185

Published: 2023

Journal Articles

Patient Cost Savings When Using Telehealth for Management of Myeloproliferative Neoplasms

Muhammad Ali Khan, Syed Arsalan Naqvi, Cecilia Y. Arana Yi, John Camoriano, Leslie Padrnos, Jennifer Andres, Joshua Blocher, Irbaz Bin Riaz, Jeanne Palmer

Blood (2023) 142 (Supplement 1): 6409.

https://doi.org/10.1182/blood-2023-187931

Published: 2023

Journal Articles

Comparative Analysis for Effectiveness of Azacitidine Versus Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes with Marrow Fibrosis: A Single Institution Experience

Ala Ebaid, MD, Shashank Y. Cingam, MBBS, Tawny Boyce, MS, MPH, Daniel Babu, MD, Qiuying Selina Liu, MD, Khine Win, Cecilia Y. Arana Yi, MD

Blood (2019) 134 (Supplement_1): 5099.

https://doi.org/10.1182/blood-2019-131881

Published: 2019

Journal Articles

Increased Frequency of Thromboses Among Patients with Philadelphia (Ph) Negative Myeloproliferative Neoplasms in New Mexico: The Role of Prothrombotic Risk Factors

Qiuying Selina Liu, MD, Shashank Y. Cingam, MBBS, Khine Z Win, MD, Tawny Boyce, MS, MPH, Cecilia Y. Arana Yi, MD

Blood (2019) 134 (Supplement_1): 5379.

https://doi.org/10.1182/blood-2019-132142

Published: 2019

Journal Articles

Expanded Access Program Of Ponatinib (AP24534) For Patients (Pts) With Refractory Chronic Myeloid Leukemia (CML) Or Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL)

Ghayathri Jeyakumar, MD, Hagop M. Kantarjian, MD, Kendra L. Sweet, MD, Cecilia Y Arana Yi, MD, Nitin Jain, MD, Elias Jabbour, MD, Alfonso Quintas-Cardama, MD, Susan O'Brien, MD, Brenda Walker, RN, Sherry R. Pierce, RN, BS, Tapan M. Kadia, MD, Farhad Ravandi, MD, Javier Pinilla, Jorge E. Cortes, MD

Blood (2013) 122 (21): 4044.

https://doi.org/10.1182/blood.V122.21.4044.4044

Published: 2013

Journal Articles

Final Report of Combination of Sorafenib, Idarubicin, and Cytarabine for Initial Therapy in Younger Patients with Acute Myeloid Leukemia

Cecilia Y Arana Yi, MD, Jorge Cortes, MD, Stefan Faderl, MD, Guillermo Garcia-Manero, MD, Marina Konopleva, MD, PhD, Zeev Estrov, MD, PhD, Susan O'Brien, M.D., Gautam Borthakur, M.D., Mark J. Levis, MD, PhD, Deborah A. Thomas, MD, Sherry A. Pierce, RN, BS, Mark Brandt, BS, Keith W. Pratz, MD, Rajyalakshmi Luthra, PhD, Michael Andreeff, MD, PhD, Hagop M. Kantarjian, MD, Farhad Ravandi, MD

Blood (2012) 120 (21): 1516.

https://doi.org/10.1182/blood.V120.21.1516.1516

Published: 2012

Journal Articles

Comparing Outcomes of Patients with Secondary AML: Treatment-Related MDS/AML, AML Secondary to Myeloproliferative Neoplasms (t-MPN), and AML with Prior Malignancies

Cecilia Y Arana Yi, MD, Hagop M. Kantarjian, MD, Guillermo Garcia-Manero, MD, William G. Wierda, MD, Ph.D., Gautam Borthakur, MD, Alfonso Quintas-Cardama, MD, Marina Konopleva, MD, PhD, Stefan Faderl, MD, Sherry A. Pierce, RN, BS, Michael Andreeff, MD, PhD, Farhad Ravandi, MD, Jorge E. Cortes, MD

Blood (2012) 120 (21): 3557.

https://doi.org/10.1182/blood.V120.21.3557.3557

Published: 2012

Journal Articles

CD33-Negative Acute Myeloid Leukemia (AML) Has Similar Characteristics to CD33-Positive Disease.

Cecilia Y. Arana Yi, MD, Wei Tan, Ph.D., Gregory Wilding, Ph.D., Laurie Ann Ford, Sheila N.J. Sait, PhD, AnneMarie W. Block, PhD, George Deeb, MD, Paul K. Wallace, MS, PhD, Petr Starostik, MD, James E. Thompson, MD, Eunice S. Wang, MD, Meir Wetzler, MD

Blood (2009) 114 (22): 4129.

https://doi.org/10.1182/blood.V114.22.4129.4129

Published: 2009

NARROW

Comparison of World Health Organization and International Consensus Classification Guidelines for Myeloid Neoplasms Harboring TP53 -Mutations Using an Independent International Cohort

Survival and Prognosis Among 301 Patients with Newly-Diagnosed Acute Myeloid Leukemia Following Venetoclax Plus Hypomethylating Agent Therapy

Phase 1/2 Multicenter, Open-Label Study of CTX-712 in Patients with Relapsed/Refractory Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes

A Phase 1 Study of CD38-Bispecific Antibody (XmAb18968) for Patients with CD38 Expressing Relapsed/Refractory Acute Myeloid Leukemia

Single-Hit TP53 mut Is Associated with Poor Outcomes in Therapy-Related but Not De Novo Myelodysplastic Syndromes: Importance of Clinical History

A Phase 1 Study of CD38-Bispecific Antibody (XmAb18968) for Patients with Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia

A Phase 1 Study of Avapritinib in Combination with Decitabine in Patients with Systemic Mastocytosis with an Associated Hematologic Neoplasm

Venetoclax + Cladribine + Low-Dose Cytarabine in Acute Myeloid Leukemia Relapsed or Refractory to Venetoclax + Hypomethylating Agent

Patient Cost Savings When Using Telehealth for Management of Myeloproliferative Neoplasms

Comparative Analysis for Effectiveness of Azacitidine Versus Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes with Marrow Fibrosis: A Single Institution Experience

Increased Frequency of Thromboses Among Patients with Philadelphia (Ph) Negative Myeloproliferative Neoplasms in New Mexico: The Role of Prothrombotic Risk Factors

Expanded Access Program Of Ponatinib (AP24534) For Patients (Pts) With Refractory Chronic Myeloid Leukemia (CML) Or Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL)

Final Report of Combination of Sorafenib, Idarubicin, and Cytarabine for Initial Therapy in Younger Patients with Acute Myeloid Leukemia

Comparing Outcomes of Patients with Secondary AML: Treatment-Related MDS/AML, AML Secondary to Myeloproliferative Neoplasms (t-MPN), and AML with Prior Malignancies

CD33-Negative Acute Myeloid Leukemia (AML) Has Similar Characteristics to CD33-Positive Disease.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only